GSK Ends Pact with Vir For New COVID Treatments
Although Flu And Respiratory Collaboration Continues
Executive Summary
Its Xevudy partner GSK is pulling out but Vir is going to carry on looking for new COVID-19 solutions independently, or with other partners.